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Dupuytren’s disease is a fibroproliferative dis-order of the palmar fascia. Diseased palmar fascia forms nodules and cords that extend into the digits. The diseased tissue can eventually contract, causing limited mobility and loss of func-tion.1 Standard treatment is aimed at correcting 
flexion deformities through surgical incision or 
excision, or collagenase treatment.2 Despite many 
patients having good outcomes from treatment, 
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Background: Dupuytren’s disease is a very common, highly heritable palmar 
fibromatosis. In a recent genome-wide association study, 26 single-nucleotide 
polymorphisms were found to be associated with development of Dupuytren’s 
disease. The authors generated a weighted genetic risk score based on the gen-
otype at these single-nucleotide polymorphisms. In two independent cohorts, 
they tested the association among high weighted genetic risk score, clinical 
features that predict a high risk of recurrence, and recurrence after surgery.
Methods: Clinical data were obtained from patient questionnaires and clini-
cal records, with missing data accounted for by imputation. Genotyping was 
performed as part of the recent genome-wide association study. Logistic re-
gression was performed to study the association among weighted genetic risk 
score, high-risk clinical features, and recurrence, with a weighted genetic 
risk score analyzed as a continuous variable, and also grouped into four 
categories.
Results: Using univariable logistic regression, a high weighted genetic risk 
score was associated with the presence of all high-risk clinical features: early 
age of onset, bilateral disease, ectopic disease, and a positive family history 
(p ≤ 0.004). After multivariable logistic regression accounting for these factors, 
an increased weighted genetic risk score was still associated with the need for 
repeated Dupuytren’s disease surgery (p = 0.004).
Conclusions: The authors’ results suggest that a weighted genetic risk score is 
useful in predicting the risk of disease recurrence, and may be used by surgeons 
to personalize prognostication. In the future, a weighted genetic risk score may 
be useful for determining the most appropriate initial surgical procedure in 
patients with Dupuytren’s disease. (Plast. Reconstr. Surg. 143: 512, 2019.)
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Dupuytren’s disease remains incurable, and surgi-
cal recurrence rates following treatment are high, 
varying from 21 to 85 percent at 5 years.3 Surgical 
complication rates in revision surgery are high.4 
There are several known clinical features that pre-
dict a more aggressive disease course and higher 
risk of recurrence in Dupuytren’s disease: age of 
onset before age 50 years, bilateral disease, ecto-
pic disease outside of the hand, and positive fam-
ily history of Dupuytren’s disease. Together, these 
factors are termed the Dupuytren’s diathesis.5
Dupuytren’s disease is known to be a complex 
disease with several genetic and environmental 
risk factors, each contributing to susceptibility to 
Dupuytren’s disease. Environmental factors asso-
ciated with Dupuytren’s disease include smoking, 
alcohol intake, diabetes, hyperlipidemia, and epi-
lepsy.6 Twin and sibling studies demonstrate the 
genetic basis of Dupuytren’s disease, and herita-
bility has been estimated at 80 percent.7,8 A pilot 
genomewide association study identified nine 
single-nucleotide polymorphisms associated with 
Dupuytren’s disease. Several of these variants 
were found on loci containing genes involved 
in the Wnt-signaling pathway, suggesting that 
abnormalities in this pathway may predispose to 
Dupuytren’s disease.9 A recent genomewide asso-
ciation study has demonstrated an additional 17 
single-nucleotide polymorphisms associated with 
a susceptibility to Dupuytren’s disease, further 
confirming the genetic basis of this disease.10
Genetic risk scores are useful tools that can be 
generated following a genome-wide association 
study to summarize the risks from multiple vari-
ants into a single variable. The basic premise is 
that a person with many risk-increasing alleles will 
have greater susceptibility to a disease, and thus a 
higher genetic risk score, than someone with only 
a few risk-increasing alleles. Genetic risk scores 
have been created in a number of diseases with 
complex genetic origins such as diabetes, where a 
weighted genetic risk score was able to differenti-
ate between type 1 and type 2 diabetes mellitus in 
adults, and monogenic and type 1 diabetes mel-
litus in neonates.11,12 The effects of each predis-
posing allele are assumed to be additive, and each 
effect allele is weighted by the natural logarithm 
of the odds ratio for that allele.
Following the pilot genome-wide association 
study, a weighted genetic risk score comprising 
only nine variants was shown to be associated with 
Dupuytren’s diathesis factors in a Dutch cohort.13 
We hypothesized that a new genetic risk score, 
constructed using the extended results from the 
recent genomewide association study, would be 
associated with diathesis in a different cohort. Fur-
thermore, we hypothesized that a weighted genetic 
risk score would also predict a higher risk of dis-
ease recurrence after surgery, thus representing a 
novel prognostic indicator that might be used in 
presurgical counseling. We report here on results 
in two independently ascertained cohorts from 
the United Kingdom and The Netherlands, show-
ing an association between a weighted genetic risk 




Each study was approved by the research eth-
ics committee or equivalent at all institutions 
where the work was carried out: the British Society 
for Surgery of the Hand Genetics of Dupuytren’s 
Disease study (United Kingdom; Oxfordshire 
Research Ethics Committee B/09/H0605/65), 
and the Genetic Origin of Dupuytren Disease and 
Associated Fibromatosis study (The Netherlands; 
Medical Ethics Committee 2007/067). All partici-
pants provided written informed consent.
Patient Populations
U.K. patients were recruited as part of the 
British Society for Surgery of the Hand Genetics 
of Dupuytren’s Disease study, and controls were 
recruited from the U.K. Household Longitudi-
nal Study, as described previously.9 Patients in 
this study were recruited from U.K. hand surgery 
centers, and must have had at least one operation 
for Dupuytren’s disease. Patients in the Dutch 
Genetic Origin of Dupuytren Disease and Associ-
ated Fibromatosis study were also recruited from 
hand surgery clinics; this recruitment has also 
been described previously.9
Clinical Data
Patients included in the British Society for Sur-
gery of the Hand Genetics of Dupuytren’s Disease 
study completed two questionnaires. An initial 
questionnaire assessed the presence of high-risk 
features that are part of the Dupuytren’s diathesis, 
namely, presence of ectopic fibrotic lesions (Led-
derhose or Peyronie disease), bilateral disease, 
age of onset younger than 50 years, and positive 
family history. A second questionnaire recorded 
details of the number of operations patients had 
undergone on each hand. Recurrence in the U.K. 
study was defined as having had more than one 
operation on the same hand.
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Data on diathesis features from Dutch partici-
pants were collected by a surgeon at entry into the 
study. Clinical data on recurrence were extracted 
from medical notes. Recurrence in the Dutch 
study was defined as a patient having undergone 
more than one operation on the same finger of 
the same hand, or having a clinical diagnosis of 
recurrence from the treating surgeon.
Genetic Risk Score
DNA was obtained from patients’ saliva (Brit-
ish Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease study) and blood (Genetic 
Origin of Dupuytren Disease and Associated Fibro-
matosis study), and genotyping was performed as 
described.10 A weighted genetic risk score was cal-










where i is the single-nucleotide polymorphism, 
n is the number of single-nucleotide polymor-
phisms genotyped for that patient, Wi is the weight 
for single-nucleotide polymorphism i (the natural 
log of the odds ratio for Dupuytren’s disease), 
and Xi is the number of risk alleles the patient 
carries of that single-nucleotide polymorphism.14 
To allow for comparison between patients when 
some single-nucleotide polymorphisms were miss-
ing, the weighted genetic risk score was divided 
by the total number of single-nucleotide polymor-
phisms genotyped and multiplied by the total of 
26 single-nucleotide polymorphisms.
Imputation and Statistical Analysis
Statistical analysis was performed in Stata 
MP14 (StataCorp, College Station, Texas) and R 
(R Foundation for Statistical Computing, Vienna, 
Austria). Quantile-quantile plot was used to dem-
onstrate the normal distribution of the weighted 
genetic risk score data. The Levene test was per-
formed to assess the equality of variances. The 
two-tailed t test was performed to test for differ-
ences between the means of weighted genetic risk 
score between cases and controls, and between 
male and female patients.
Before imputation, in the British Society for Sur-
gery of the Hand Genetics of Dupuytren’s Disease 
study, we excluded 48 samples that had been geno-
typed at a single single-nucleotide polymorphism, 
and would therefore violate the missing at random 
assumption. We then accounted for missing clinical 
data and weighted genetic risk score by imputation 
in our remaining 6126 individuals using multiple 
imputation by chained equations.15 We imputed 
missing data on family history, early onset, bilateral 
disease, recurrence, sex, and weighted genetic risk 
score. Ectopic disease was not imputed, as there 
were no missing data. We created 75 imputed data 
sets, each using 100 cycles of imputation, with the 
following input variables: recurrence, weighted 
genetic risk score, family history, early onset, ecto-
pic disease, bilateral disease, and sex. In the Genetic 
Origin of Dupuytren Disease and Associated Fibro-
matosis study, we imputed the missing data using 
the same method as in the British Society for Sur-
gery of the Hand Genetics of Dupuytren’s Disease 
study, with the additional variable ectopic disease 
included in the imputation chain.
After imputation, we analyzed 6126 individu-
als in the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease study and 1730 
individuals in the Genetic Origin of Dupuytren 
Disease and Associated Fibromatosis study. Uni-
variable logistic regression was performed to test 
for associations between each diathesis feature 
and recurrence in the British Society for Surgery 
of the Hand Genetics of Dupuytren’s Disease 
study. We analyzed weighted genetic risk score in 
two ways: first, in four groups with mean − 1 SD, 
mean, and mean + 1 SD as thresholds; second, 
as a continuous variable. We used multivariable 
logistic regression to test for associations between 
category of weighted genetic risk score, diathe-
ses, and recurrence. We used univariable logis-
tic regression to test for the association between 
increasing value of weighted genetic risk score 
and recurrence. Meta-analysis was performed 
using the fixed effect inverse variance method. 




High-risk features of the Dupuytren’s diathe-
sis were common in both cohorts (Table 1). The 
ratio of male to female patients was approximately 
3:1, and the percentage of individuals with each 
feature was broadly similar across cohorts. Bilat-
eral disease was the most common diathesis fea-
ture, reported at 63 percent and 40 percent in the 
British Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease study and the Genetic Origin 
of Dupuytren Disease and Associated Fibromato-
sis study, respectively. The least common diathesis 
feature was ectopic disease, reported at less than 
13 percent in both cohorts.
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Weighted Genetic Risk Score
After genomewide association study quality 
control, the majority of individuals from the dis-
covery cohort of the British Society for Surgery of 
the Hand Genetics of Dupuytren’s Disease study 
were successfully genotyped at all 26 single-nucle-
otide polymorphisms. In the Genetic Origin of 
Dupuytren Disease and Associated Fibromatosis 
cohort, the majority were directly genotyped at 22 
loci. (See Table, Supplemental Digital Content 1, 
which shows the distribution of weighted genetic 
risk score single-nucleotide polymorphism count 
in the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease study and the 
Genetic Origin of Dupuytren Disease and Asso-
ciated Fibromatosis study, http://links.lww.com/
PRS/D260.) 
In the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease study, the cal-
culated weighted genetic risk score ranged from 
3.48 to 9.76, with a mean of 6.32. As expected, 
cases had a higher mean weighted genetic risk 
score than controls (6.32 versus 5.44; p < 0.001). 
Within cases, women had a higher mean weighted 
genetic risk score than men (6.42 versus 6.29; 
p < 0.001). In the Genetic Origin of Dupuytren Dis-
ease and Associated Fibromatosis study, weighted 
genetic risk score ranged from 3.00 to 9.77, with a 
mean of 6.26. Here, women had a mean weighted 
genetic risk score similar to that for men (6.27 
versus 6.25; p = 0.70). In both cohorts, weighted 
genetic risk score was distributed normally. [See 
Figure, Supplemental Digital Content 2, which 
shows the quantile-quantile plot, demonstrat-
ing the Gaussian nature of the weighted genetic 
risk score distribution in both (above) the Brit-
ish Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease study and (below) the Genetic 
Origin of Dupuytren Disease and Associated 
Fibromatosis study. wGRS, wighted genetic risk 
score, http://links.lww.com/PRS/D261.] 
Weighted Genetic Risk Score Is Associated with 
Dupuytren’s Diathesis in the British Society for 
Surgery of the Hand Genetics of Dupuytren’s 
Disease Study
In the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease cohort, multino-
mial logistic regression analysis demonstrated sig-
nificant associations between each diathesis factor 
and the two highest weighted genetic risk score 
categories (Table 2). The odds ratios of express-
ing a particular Dupuytren’s diathesis feature 
consistently increased for each additional unit of 
weighted genetic risk score (Table 3).
Dupuytren’s Diathesis Is Associated with 
Recurrence in the British Society for Surgery 
of the Hand Genetics of Dupuytren’s Disease 
Cohort
Each diathesis feature predicted higher odds 
of requiring further surgery in the British Society 
for Surgery of the Hand Genetics of Dupuytren’s 
Disease study: early age of onset was the strongest 
predictor (OR, 2.38; 95 percent CI, 2.00 to 2.83; 
p < 0.001) (Table 4). The odds of further surgery 
also increased with increasing number of diathe-
sis features (Table 5).
Table 2. Association between Dupuytren’s 
Diathesis and Weighted Genetic Risk Score in the 
British Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease Cohort
Diathesis and  
wGRS Group OR (95% CI) p 
Bilateral disease   
  Base   
  2 1.26 (1.07–1.50) 0.007
  3 1.45 (1.22–1.73) <0.001
  4 1.78 (1.44–2.19) <0.001
Early age of onset   
  Base   
  2 1.11 (0.92–1.35) 0.274
  3 1.21 (1.00–1.47) 0.059
  4 1.38 (1.10–1.73) 0.006
Ectopic disease   
  Base   
  2 1.20 (0.90–1.59) 0.220
  3 1.52 (1.14–2.01) 0.004
  4 1.99 (1.46–2.70) <0.001
Positive family history   
  Base   
  2 1.14 (0.96–1.35) 0.137
  3 1.29 (1.08–1.53) 0.004
  4 1.38 (1.13–1.68) 0.002
wGRS, weighted genetic risk score







Male 4797 (78.3) 1311 (75.8)
Missing 25 (0.4) 3 (0.2)
Bilateral disease 3860 (63) 692 (40)
Missing 36 (0.6) 606 (35)
Early age of onset 1553 (25.3) 627 (36.2)
Missing 1140 (18.6) 126 (7.3)
Ectopic disease 719 (11.7) 219 (12.7)
Missing 0 (0) 618 (35.7)
Positive family history 2391 (39) 846 (48.9)
Missing 36 (0.6) 447 (25.8)
Recurrence 1055 (17.2) 239 (13.8)
Missing 2682 (43.8) 1007 (58.2)
BSSH-GODD, British Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease; GODDAF, Genetic Origin of Dupuytren Dis-
ease and Associated Fibromatosis.
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Weighted Genetic Risk Score Is Associated with 
Recurrence in the British Society for Surgery of 
the Hand Genetics of Dupuytren’s Disease and 
the Genetic Origin of Dupuytren Disease and 
Associated Fibromatosis Cohorts
In the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease cohort, both 
in unadjusted models and after adjustment for 
bilateral disease, ectopic disease, early onset, 
and positive family history, recurrence increased 
with increasing weighted genetic risk score cat-
egory (Table 6). In the highest weighted genetic 
risk score category, the adjusted odds ratio for 
recurrence was 1.46 (95 percent CI, 1.09 to 1.96; 
p = 0.008). With each unit increase in weighted 
genetic risk score, the odds ratio for recurrence 
was 1.18 (95 percent CI, 1.06 to 1.31; p = 0.002) 
(Table 7).
In the Genetic Origin of Dupuytren Disease 
and Associated Fibromatosis cohort, recurrence 
was also correlated with weighted genetic risk 
score in unadjusted models, with an odds ratio 
of 1.88 (95 percent CI, 1.11 to 3.17; p = 0.019) 
between the highest and lowest categories. With 
each unit increase in weighted genetic risk score, 
the increased odds ratio for recurrence was 1.22 
(95 percent CI, 1.01 to 1.46; p = 0.035) (Table 6). 
However, when we adjusted for diathesis factors, 
these results lost statistical significance, most likely 
because of the small size of this cohort. Despite 
this, the magnitude and direction of the associa-
tion with recurrence is consistent across cohorts 
(Table 7).
DISCUSSION
In this study, we show that patients with high 
weighted genetic risk scores are more susceptible 
to recurrence following surgery for Dupuytren’s 
disease. Importantly, this was demonstrated in 
patients from two different populations, ascer-
tained through independently designed stud-
ies. Using logistic regression, we demonstrated 
that the increased risk of recurrence predicted 
by weighted genetic risk score is independent of 
clinical features known to associate with aggres-
sive, highly recurrent disease—the Dupuytren’s 
diathesis.
Previous work based on the results of our pilot 
genome-wide association study had demonstrated 
an association between an early version of the 
weighted genetic risk score, composed of nine sin-
gle-nucleotide polymorphisms, and some features 
of Dupuytren’s diathesis (i.e., ectopic disease, 
early age of onset, and positive family history).13 
This study confirms and extends this association 
in a larger cohort, to include bilateral disease.
Genetic risk scores work on the assumption that 
each included single-nucleotide polymorphism is 
independently associated with an increased risk 
for the tested variable. Using a weighted genetic 
risk score, rather than testing each single-nucleo-
tide polymorphism individually, has more power 
because the effects of the single-nucleotide poly-
morphisms are summed, and no multiple testing 
correction is needed. Our genetic risk score was 
a weighted model rather than an additive model, 
in which the presence of each single-nucleotide 
polymorphism would equally increase the score. 
This weight was determined on the basis of the 
odds ratio of the single-nucleotide polymorphism 
when considering predisposition to Dupuytren’s 
disease as a whole. This makes the assumption that 
a single-nucleotide polymorphism contributes to 
diathesis and recurrence with a similar weight to 
its overall predisposition to disease. Therefore, 
one weakness of our weighted genetic risk score is 
Table 3. Odds of Expressing a Dupuytren’s Diathesis 
Feature for Each Increasing Unit of Weighted Genetic 
Risk Score in the British Society for Surgery of the 
Hand Genetics of Dupuytren’s Disease Cohort
Diathesis OR (95% CI) p
Bilateral disease 1.26 (1.17–1.35) <0.001
Early age of onset 1.13 (1.04–1.23) 0.004
Ectopic disease 1.31 (1.18–1.46) <0.001
Positive family history 1.14 (1.07–1.22) <0.001
Table 4. Odds Ratio of Recurrence for Each Diathesis 
Feature in the British Society for Surgery of the Hand 
Genetics of Dupuytren’s Disease Cohort
Diathesis OR (95% CI) p 
Bilateral disease 2.20 (1.85–2.61) <0.001
Early age of onset 2.38 (2.00–2.83) <0.001
Ectopic disease 1.73 (1.40–2.14) <0.001
Positive family history 1.61 (1.39–1.86) <0.001
Table 5. Odds Ratio of Recurrence for Increasing 
Number of Diathesis Features in the British Society 
for Surgery of the Hand Genetics of Dupuytren’s 
Disease Cohort
No. of Diathesis  
Features OR (95% CI) p
0 Base —
1 1.68 (1.36–2.08) <0.001
2 2.90 (2.31–3.65) <0.001
3 4.68 (3.50–6.26) <0.001
4 7.50 (4.76–11.83) <0.001
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that these single-nucleotide polymorphisms were 
selected because they are known risk factors for 
Dupuytren’s disease—they are not necessarily risk 
factors for recurrence or diathesis per se. Includ-
ing single-nucleotide polymorphisms that may not 
associate with recurrence increases the noise and 
consequently reduces the power of our model.
In our study, we used two definitions of recur-
rence as made necessary by the different methods 
of data collection for the two cohorts. No univer-
sal definition of recurrent Dupuytren’s disease 
exists.16,17 The definition of recurrence in the 
Genetic Origin of Dupuytren Disease and Asso-
ciated Fibromatosis study, being multiple opera-
tions in the same finger of the same hand, will 
not include patients who rejected further treat-
ment after surgery, or patients who had further 
treatment in a different hospital that was not 
detected by our study. The definition in the Brit-
ish Society for Surgery of the Hand Genetics of 
Dupuytren’s Disease study is a second operation 
on the same hand. This may exclude individuals 
who refuse further surgery for recurrent disease, 
and it will also include instances where patients 
have undergone surgery in stages, with different 
fingers operated on at different times. Although 
our definitions have limitations, it is compelling 
that two separate definitions of recurrence led 
to consistent results. Our conclusions remain 
important for patient counseling. If a patient has 
a high weighted genetic risk score, and/or many 
diathesis features are present, they are more likely 
to have an aggressive disease course and require 
repeated surgery.
A further limitation of our work is that we are 
unable to provide detailed analysis of subgroups 
of patients (e.g., classified by initial severity of 
contracture or initial surgical treatment). Further-
more, we cannot correlate our weighted genetic 
risk score to the time from initial treatment to 
recurrence. These outstanding questions are 
interesting areas for future research.
With improved access to whole-genome sequenc-
ing in clinical settings, counseling on the basis of 
genetic risk scores may soon become realistic for a 
variety of surgical diseases. Presently, patients with 
Dupuytren’s disease are counseled based on clinical 
diathesis factors only. Including weighted genetic 
risk score may improve the accuracy of counsel-
ing, especially as many patients present to clinicians 
before the full extent of their diathesis has become 
apparent. More work is needed to confirm how 
Table 6. Risk of Dupuytren’s Disease Recurrence by Weighted Genetic Risk Score Category in the British 
Society for Surgery of the Hand Genetics of Dupuytren’s Disease and Genetic Origin of Dupuytren Disease and 
Associated Fibromatosis Cohorts
Cohort and wGRS  
Category
Unadjusted Adjusted*
OR (95% CI) p OR (95% CI) p 
BSSH-GODD study     
  Base     
  2 1.23 (1.00–1.53) 0.06 1.16 (0.93–1.46) 0.177
  3 1.48 (1.17–1.86) 0.001 1.35 (1.06–1.71) 0.009
  4 1.69 (1.28–2.23) <0.001 1.46 (1.09–1.96) 0.008
GODDAF study     
  Base     
  2 1.43 (0.92–2.22) 0.107 1.31 (0.82–2.09) 0.257
  3 1.50 (0.94–2.42) 0.09 1.09 (0.80–2.18) 0.276
  4 1.88 (1.11–3.17) 0.019 1.58 (0.90–2.77) 0.111
wGRS, weighted genetic risk score; BSSH-GODD, British Society for Surgery of the Hand Genetics of Dupuytren’s Disease; GODDAF, Genetic 
Origin of Dupuytren Disease and Associated Fibromatosis.
*Adjusted for bilateral disease, ectopic disease, early onset, and positive family history.
Table 7. Increased Risk of Recurrence for Each Unit Increase in Weighted Genetic Risk Score
Cohort
Unadjusted Adjusted*
OR (95% CI) p OR (95% CI) p 
BSSH-GODD study 1.25 (1.13–1.38) <0.001 1.18 (1.06–1.31) 0.002
GODDAF study 1.22 (1.01–1.46) 0.035 1.14 (0.94–1.39) 0.194
Meta-analysis 1.24 (1.12–1.39) <0.001 1.17 (1.05–1.31) 0.004
BSSH-GODD, British Society for Surgery of the Hand Genetics of Dupuytren’s Disease; GODDAF, Genetic Origin of Dupuytren Disease and 
Associated Fibromatosis.
*Adjusted for bilateral disease, ectopic disease, early onset, and positive family history.
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patients with different weighted genetic risk scores 
respond to different treatment modalities. This 
will be another step along the road to personalized 
treatment for our patients.
CONCLUSIONS
We have demonstrated that a weighted genetic 
risk score predicts recurrence after surgery in 
Dupuytren’s disease, a very common complex 
fibroproliferative disease of the palmar fascia. This 
predictive value is independent of known high-risk 
clinical features. Knowledge of this weighted genetic 
risk score might facilitate more accurate prognosti-
cation for the individual patient, and in the future 
may influence the choice of initial treatment.
Dominic Furniss, D.M.
Botnar Research Centre
Nuffield Department of Orthopaedics,  
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